Neuromuscular Study Group 2023 (NMSG)

Back

A Phase 1/2 Randomized, Placebo-Controlled, Multiple Ascending Dose Study (ACHIEVE) of DYNE-101 in Individuals with Myotonic Dystrophy Type 1 (DM1) (poster)

View

A Phase 1/2 Study of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping: DELIVER Study Design (poster)

View

©2026 Dyne Therapeutics, Inc. All rights reserved MED-00978. Date of preparation: July 2026.